following an abbreviated submission:
trientine tetrahydrochloride (Cuprior®) is accepted for use within NHSScotland.
Indication under review: the treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy.
Trientine tetrahydrochloride is an alternative to another formulation of trientine with a lower budget impact.
Download detailed advice438KB (PDF)
- Medicine name:
- trientine tetrahydrochloride (Cuprior)
- SMC ID:
For the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.
- Pharmaceutical company
- GMP-Orphan United Kingdom Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published:
- 11 November 2019